Back

Comparison of triple oral and triple parenteral combination therapy in pulmonary arterial hypertension

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Treatment of pulmonary hypertension Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Francesco Chietera

S. Orsola-Malpighi Policlinic, Bologna (Italy)

6 More presentations in this session

Presentation thumbnail
Representativeness of randomized clinical trial criteria among the real-world patients with pulmonary arterial hypertension: an analysis from the FOCUS-PAH registry
Doctor E. Bertarelli (Trieste, IT)
Abstract Slides Video
Presentation thumbnail
Pediatric pulmonary arterial hypertension: characteristics and efficacy of specific therapy on clinical, echocardiographic and hemodynamic parameters
Doctor M. Salvi (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Hemodynamic effects of add-on therapies in pulmonary arterial hypertension: an additive component network meta-analysis.
Mr I. Farmakis (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Pulmonary artery denervation for pulmonary hypertension-a systematic review and meta-analysis
Associate Professor E. Cekirdekci (Kyrenia, CY)
Abstract Slides Video
Presentation thumbnail
Dramatic differences resulting from treatment timing of treprostinil in high-risk patients: a real-world data analysis
Doctor Y. Kim (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Treatment of pulmonary hypertension

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of selexipag based triple combination targeted drug therapy in chinese patients with pulmonary arterial hypertension
thumbnail
Congress Presentation
Could we maintain the initial efficacy of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : Insights from a single-centre study
thumbnail
Congress Presentation
Dramatic differences resulting from treatment timing of treprostinil in high-risk patients: a real-world data analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources